Cipher Pharmaceuticals Inc (CPHRF)
Cipher Pharmaceuticals Inc. is a Canadian specialty pharmaceutical company based in Mississauga, Ontario. The company markets a range of prescription products, including Epuris for severe acne, Actikerall for actinic keratosis, Vaniqa for reducing unwanted facial hair growth in women, Durela for pain management, Brinavess for the conversion of recent-onset atrial fibrillation, Aggrastat for acute coronary syndrome, and Natroba for the topical treatment of head lice and scabies. Its licensed portfolio also includes Absorica, Conzip, and Lipofen. Cipher’s development pipeline includes piclidenoson CF-101 for plaque psoriasis and rheumatoid arthritis, MOB-015 for onychomycosis, and DTR-001, a tattoo removal cream. Founded in 2000, the company’s common stock is listed on OTC Markets.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-CPHR.F
|
$9.82
|
-16.1% Downside
|
Fair
|
—
|
—
|
—
|
Great
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
9.6x
|
2.2x
|
5.8x
|
296.6 M
|
289.7 M
|
0.1%
|
58.4%
|
18.0
|
—
|
97.2%
|
